Evzio

Description

Evzio (naloxone injection)

Background
Evzio is a single-use auto-injector that contains naloxone hydrochloride. Naloxone is an opioid antagonist that directly counteracts the effect of opioid medications by competing for the same drug receptors. In cases of opioid drug overdose, this competitive inhibition helps reverse the depressant effects of opioid agonists. Opioid reversal is key in turning back the respiratory depression, CNS sedation, and low blood pressure associated with opioid overdose (1-2).

Naloxone is commercially available in the following dosage forms: liquid nasal spray, auto-injector solution, injectable vial solution, injectable cartridge solution, and pre-filled syringe solution.

Regulatory Status
FDA approved indication: Evzio is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

1. Evzio is intended for immediate administration as emergency therapy in settings where opioids may be present.
2. Evzio is not a substitute for emergency medical care (1-2).
Evzio is approved to use in anyone of any age that is suffering from suspected or known opioid overdose with slight differences in the technique used for administration based on the age of the patient (1-2).

**Related policies**

**Policy**

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Evzio may be considered **medically necessary** in an auto-injector formulation for the treatment of patients with suspected or known opioid overdose or high risk of suspected opioid overdose and if the conditions indicated below are met.

Evzio may be considered **investigational** for all other indications.

**Prior-Approval Requirements**

**Diagnoses**

Patient must have **ONE** of the following:

1. Emergency treatment for suspected or confirmed opioid overdose
2. High risk of suspected opioid overdose

**AND ALL** of the following:

a. Inadequate response, intolerance or contraindication to Narcan nasal spray and generic naloxone (vials)

**Prior – Approval Renewal Requirements**

Same as Above

**Policy Guidelines**

**Pre - PA Allowance**

None
Prior - Approval Limits

<table>
<thead>
<tr>
<th>Strength</th>
<th>Quantity and Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.4mg</td>
<td>1 carton (2 auto-injectors) per 180 days OR</td>
</tr>
<tr>
<td>2mg</td>
<td>1 carton (2 auto-injectors) per 180 days</td>
</tr>
</tbody>
</table>

Duration 6 months

Prior – Approval Renewal Limits

<table>
<thead>
<tr>
<th>Strength</th>
<th>Quantity and Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.4mg</td>
<td>1 carton (2 auto-injectors) per 180 days OR</td>
</tr>
<tr>
<td>2mg</td>
<td>1 carton (2 auto-injectors) per 180 days</td>
</tr>
</tbody>
</table>

Duration 6 months

Rationale

Summary
Opioid receptor antagonists have respiratory and CNS depression reversal properties for opioid overdose. Evzio is FDA-approved for the reversal of known or suspected opioid overdose by competitive antagonism of key receptors in patients of any age. Naloxone is a pregnancy category B drug that should be used only in cases of clear benefit. The safety and efficacy of naloxone have been established in pediatric patients with numerous clinical studies as well as post-marketing data and clinical practice guidelines. Naloxone is commercially available in the following dosage forms: liquid nasal spray, auto-injector solution, injectable vial solution, injectable cartridge solution, and pre-filled syringe (1-2).

Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of Evzio while maintaining optimal therapeutic outcomes.

References

1. Evzio 0.4mg [package insert]. Richmond, VA, Kaleo Inc.; April 2014.

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 2016</td>
<td>New addition to PA</td>
</tr>
<tr>
<td>January 2017</td>
<td>Addition of 2mg strength to approval limits</td>
</tr>
<tr>
<td>June 2017</td>
<td>Annual editorial review and reference update</td>
</tr>
<tr>
<td>June 2018</td>
<td>Annual editorial review</td>
</tr>
<tr>
<td>June 2019</td>
<td>Annual review</td>
</tr>
</tbody>
</table>

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 20, 2019 and is effective on July 1, 2019.